Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

This is the logo of the provider
AASLD 2026 5 - 9 November 2026

Semaglutide 2.4 mg and the changes in liver enzymes and cardiometabolic markers in patients with MASH: a descriptive real-world data study

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
RWE